BioSpace News Archive

Advanced Chemotherapy Technologies (ACT), Inc., a clinical-stage drug delivery company, announced today that it has been awarded a Phase IIb Small Business Innovation research (SBIR) grant expected to total $4 million over two years from the National Cancer Institute, part of the National Institutes of Health.

NRx Pharmaceuticals today announced that management will report second quarter 2021 financial results after the market close on August 16, 2021. The company will host a conference call and webcast on August 17, 2021, 8:30 AM Eastern Time to discuss its results and provide a clinical and corporate update.

Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that it will release financial results for the first half of 2021 on Tuesday, August 31, 2021, after the US markets close.

Evofem Biosciences, Inc today reported financial results for the three- and six-month periods ended June 30, 2021.

Mirus Bio, today announces the launch of the TransIT ® VirusGEN ® GMP product line.

Cardax, Inc. announced the filing of a Form 15 with the U.S. Securities and Exchange Commission to voluntarily suspend its reporting obligations under Section 15 of the Securities Exchange Act of 1934.

MDxHealth SA, a commercial-stage innovative precision diagnostics company, announced it will release its financial results for the half year ended June 30, 2021, after market close of the Brussels Stock Exchange on Thursday August 26, 2021.

GC Pharma (006280.KS) today announced that Frontiers in Immunology has published the safety and final efficacy results from the pivotal Phase III clinical trial of GC5107, its 10% Immune Globulin product for intravenous administration.

Innovent Biologics, Inc. (Innovent) (HKEX: 01801), announces today that the primary endpoint was met in the phase 3 study CREDIT-2 of recombinant fully human anti-PCSK-9 monoclonal antibody (R&D code: IBI306, independently developed by Innovent) for the treatment of Chinese heterozygous familial hypercholesterolemia (HeFH).

Fulcrum Therapeutics, Inc. announced that it has priced an underwritten public offering of 6,600,000 shares of its common stock at a public offering price of $19.00 per share, for total gross proceeds of approximately $125 million, before deducting underwriting discounts and commissions and offering expenses payable by Fulcrum.